6.79
-0.20 (-2.86%)
| Previous Close | 6.99 |
| Open | 7.20 |
| Volume | 1,086,808 |
| Avg. Volume (3M) | 1,313,810 |
| Market Cap | 397,431,584 |
| Price / Sales | 2.11 |
| Price / Book | 0.860 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.50 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 79.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 31 Mar 2025 | 1,650,000 |
| Ecor1 Capital, Llc | 31 Mar 2025 | 1,462,328 |
| Opaleye Management Inc. | 31 Mar 2025 | 1,195,000 |
| Forbes J M & Co Llp | 31 Mar 2025 | 1,094,564 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 May 2025 | Announcement | Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer |
| 20 May 2025 | Announcement | 4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market |
| 08 May 2025 | Announcement | Twist Bioscience and Ginkgo Bioworks Revise Collaboration |
| 06 May 2025 | Announcement | Ginkgo Bioworks Reports First Quarter 2025 Financial Results |
| 30 Apr 2025 | Announcement | Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors |
| 29 Apr 2025 | Announcement | Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation |
| 22 Apr 2025 | Announcement | Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation |
| 10 Apr 2025 | Announcement | Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |